Key trends to watch
The trends shaping drug development and patient health outcomes in 2025 and beyond
Regulators are prioritizing equitable health access and patient preferences, underscoring the need for innovators to demonstrate the value of their products using emerging tools such as patient-reported outcomes and AI/machine learning. 2024 saw a number of regulatory firsts, including novel treatments for Niemann-Pick disease type C and GNE myopathy, as well as the first tumor infiltrating lymphocite treatment to win approval. Meanwhile, GLP-1s are revolutionizing treatment of obesity and diabetes while the emergence of radiopharmaceuticals promises leaps in the treatment and diagnosis of a plethora of diseases.
These trends demonstrate the industry’s continuing innovation as well as regulatory agencies’ commitment to filling treatment gaps for patient populations with high unmet needs.
Read more in our Blog section.
